CNTN1

CNTN1 is a glycosylphosphatidylinositol (GPI)-anchored neuronal cell-surface adhesion molecule built from six C2 Ig domains and four fibronectin type III repeats, whose anchoring and architecture were established by direct biochemical characterization (PMID:7959734). At the neuronal surface it binds the tenascin-R–RPTPζ complex and serves as a receptor that nucleates perineuronal net assembly [PMID:bio_10.1101_2024.11.05.622114]. Manipulation of CNTN1 in defined brain regions links it to circuit-level plasticity and neuroinflammation: hippocampal overexpression activates microglia, drives astrocyte activation with aberrant EAAT1/EAAT2 glutamate-transporter expression, and impairs long-term potentiation and cognition, effects reversed by the microglial inhibitor minocycline, and additionally produces anxiety- and depression-like phenotypes with reduced hippocampal neurogenesis (PMID:33737174, PMID:37196127). In the nucleus accumbens, CNTN1 is induced by methamphetamine through dopamine D2 receptor signaling and supports addiction-related conditioned place preference and expression of the synaptic proteins NR2A, NR2B, and PSD95 (PMID:37014368). Anti-CNTN1 autoantibodies cause peripheral nerve conduction block via complement deposition at paranodes, implicating CNTN1 in node-of-Ranvier integrity (PMID:30953561). Beyond the nervous system, CNTN1 is a consistent pro-tumorigenic factor across prostate, lung, cholangiocarcinoma and other cancers, where it drives invasion, epithelial-mesenchymal transition, metastasis, and chemoresistance largely through activation of PI3K/AKT signaling (PMID:26795349, PMID:28934754, PMID:41898278).

1. 1994 High

   Established the fundamental molecular identity of CNTN1 as a GPI-anchored multidomain cell-surface protein, defining the structural basis for its adhesion/receptor function.

   Evidence PI-PLC cleavage, [3H]-ethanolamine metabolic labeling, and cDNA cloning in transfected cells

   PMID:7959734

   Open questions at the time

   • No binding partners or downstream signaling identified at this stage
   • No functional or cellular role assigned
2. 2016 Medium

   Showed CNTN1 is not merely structural but functionally drives malignant behavior, connecting it to AKT activation and loss of E-cadherin in prostate cancer.

   Evidence Gain/loss-of-function in DU145 cells, invasion assays, xenograft metastasis model, Western blot

   PMID:26795349

   Open questions at the time

   • Mechanism linking GPI-anchored CNTN1 to intracellular AKT activation unresolved
   • Direct receptor partner in cancer cells not identified
   • Single lab, single tumor type
3. 2017 Medium

   Extended the cancer role to chemoresistance, implicating CNTN1-driven EMT via PI3K/Akt as a mechanism of cisplatin resistance.

   Evidence Reciprocal overexpression/knockdown in A549 and A549/DDP cells, EMT and pathway Western blots, xenograft

   PMID:28934754

   Open questions at the time

   • How CNTN1 engages PI3K/Akt mechanistically not shown
   • No structural basis for pathway activation
4. 2020 Medium

   Reinforced the PI3K/Akt-EMT-resistance axis in docetaxel-resistant prostate cancer, supporting CNTN1 as a therapeutic target in drug-resistant tumors.

   Evidence shRNA knockdown in resistant PCa lines, multiple phenotypic assays, pathway Western blot, xenograft

   PMID:33488868

   Open questions at the time

   • Upstream regulators of CNTN1 in resistance not defined
   • Direct signaling intermediates unmapped
5. 2021 Medium

   Demonstrated a causal CNS role beyond adhesion, linking hippocampal CNTN1 to neuroinflammation, mood phenotypes, and impaired neurogenesis.

   Evidence AAV CNTN1 overexpression, behavioral tests, cytokine qPCR, doublecortin immunohistochemistry in mice

   PMID:33737174

   Open questions at the time

   • Mechanism by which surface CNTN1 activates microglia unknown
   • Cell-type origin of inflammatory signal undefined
6. 2023 Medium

   Resolved a microglia-astrocyte-glutamate transporter circuit through which CNTN1 impairs synaptic plasticity, with pharmacological rescue confirming microglia as the initiating node.

   Evidence AAV overexpression, cognition tests, LTP electrophysiology, minocycline rescue, EAAT1/EAAT2 Western blot

   PMID:37196127

   Open questions at the time

   • Receptor mediating CNTN1's effect on microglia not identified
   • Whether endogenous CNTN1 elevation produces the same effect untested
7. 2023 Medium

   Placed CNTN1 within addiction circuitry, showing it acts downstream of dopamine D2 signaling to support synaptic protein expression and drug-associated behavior in the nucleus accumbens.

   Evidence NAc-specific AAV-shRNA knockdown, conditioned place preference, haloperidol treatment, NR2A/NR2B/PSD95 Western blot

   PMID:37014368

   Open questions at the time

   • Direct link from D2 signaling to CNTN1 transcription not delineated
   • Synaptic partners of CNTN1 in NAc not identified
8. 2024 Medium

   Identified the physiological surface ligand complex (tenascin-R–RPTPζ) and assigned CNTN1 a structural role nucleating perineuronal nets, defining its canonical neural receptor function.

   Evidence Biochemical binding and structural analysis with Cntn1 loss-of-function in PNN formation (preprint)

   PMID:bio_10.1101_2024.11.05.622114

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Stoichiometry and signaling consequences of the ternary complex unresolved
9. 2025 Low

   Began to define upstream regulation of CNTN1 in cancer, implicating PFKM-driven histone lactylation at the CNTN1 promoter and a direct PFKM–CNTN1 interaction in gastric cancer.

   Evidence Luciferase reporter for H3K18la regulation, Co-IP, CNTN1 overexpression rescue, viability/invasion assays, xenograft

   PMID:40608258

   Open questions at the time

   • Single lab with limited mechanistic detail; epigenetic mechanism not fully characterized
   • Reciprocal validation of PFKM–CNTN1 interaction lacking
10. 2025 Low

    Proposed a CNTN1–PSEN1 regulatory axis driving ovarian cancer proliferation and invasion, expanding CNTN1's downstream effector repertoire.

    Evidence siRNA knockdown, luciferase reporter, PSEN1 overexpression rescue, colony formation/transwell assays, xenograft

    PMID:40687216

    Open questions at the time

    • Single rescue experiment; molecular nature of CNTN1–PSEN1 regulation undefined
    • Not independently confirmed
11. 2026 Medium

    Confirmed the PI3K-AKT/EMT invasion-metastasis program as a recurrent CNTN1 mechanism across additional tumor types, here hilar cholangiocarcinoma.

    Evidence Reciprocal gain/loss-of-function, Transwell invasion, orthotopic metastasis model, pathway and EMT Western blots

    PMID:41898278

    Open questions at the time

    • Direct molecular link between GPI-anchored CNTN1 and PI3K activation still unresolved
    • Cancer-relevant binding partner not identified

• The mechanistic bridge connecting CNTN1's extracellular GPI-anchored adhesion function to its consistent intracellular PI3K/AKT activation in cancer, and the identity of the transmembrane co-receptor transducing this signal, remains unresolved.
• No transmembrane signaling partner for CNTN1 identified in cancer
• Whether neural ligands (tenascin-R/RPTPζ) operate in tumor contexts untested
• No structure of CNTN1 in a signaling-competent complex with PI3K pathway components